De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant gliomaDiana D. Shi, William G. Kaelin, Yu‐Fen Lin et al.|Cancer Cell|2022Cited by 132
De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant GliomaDiana D. Shi, Samuel K. McBrayer, Milan R. Savani et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 11
Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma ModelDerek Shi, Samuel K. McBrayer, A.C. Wang et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 2
TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENEDiana D. Shi, Samuel K. McBrayer, Adam Wang et al.|Neuro-Oncology|2020Cited by 1
A Case of Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative DisorderShalini Vemula, Michael M. Levitt|SKIN The Journal of Cutaneous Medicine|2025Cited by 0